

### EDITOR-IN-CHIEF

Laura L. Kiessling University of Wisconsin, Madison

### BOARD OF EDITORS

Jennifer A. Doudna University of California, Berkeley Kai Johnsson

Ecole Polytechnique Fédérale de Lausanne Anna K. Mapp University of Michigan, Ann Arbor

Michael A. Marletta University of California, Berkeley Peter H. Seeberger

Eidgenössische Technische Hochschule James R. Williamson The Scripps Research Institute

### EDITORIAL ADVISORY BOARD

Carolyn R. Bertozzi University of California, Berkeley Brian T. Chait Rockefeller University Tim Clackson ARIAD Pharmaceuticals, Inc. Jon C. Clardy Harvard Medical School

Benjamin F. Cravatt The Scripps Research Institute

Peter B. Dervan California Institute of Technology

Rebecca W. Heald University of California, Berkeley Linda C. Hsieh-Wilson California Institute of Technology Tony Hunter

Salk Institute

Stephen C. Kowalczykowski University of California, Davis Richard H. Kramer

University of California, Berkeley Thomas V. O'Halloran

Northwestern University Hiroyuki Osada

RIKEN Anna M. Pyle

Yale University Ronald T. Raines

University of Wisconsin, Madison

Charles Sawyers University of California, Los Angeles

Stuart L. Schreiber Harvard University Peter G. Schultz

The Scripps Research Institute Michael P. Sheetz Columbia University

H. Ulrich Stilz Sanofi-Aventis, Frankfurt Christopher T. Walsh Harvard Medical School

## **Screening for Success**

or almost two decades, the pharmaceutical and biotech industries have been using high-throughput screening (HTS) to obtain small-molecule hits against validated biological targets. Although these industries have amassed a wealth of data and experience on target selection, technology development, and hit validation, resources for HTS have not always been readily available to researchers in academia and in government institutions. But times are changing, thanks in part to the advent of the National Institutes of Health (NIH) Molecular Libraries Roadmap. This endeavor—consisting of a network of small-molecule screen-

ing centers, the PubChem database for small-molecule and screening data, and resources for technology development has helped researchers outside of industry utilize HTS to identify chemical compounds that modulate the activities of biological targets (1).

This is an important advance for the field of chemical biology. HTS in an academic environment is expanding the diversity of both chemical compounds and biological targets



beyond those pursued in industrial drug discovery, where the goal is to identify drug leads for targets associated with human diseases. It is encouraging to note that more and more academic researchers are utilizing HTS to identify small molecules that modulate biological processes in their favorite organisms. HTS is also a key component in large public projects. For example, the NIH Chemical Genomics Center, the Environmental Protection Agency, and the National Toxicology Program are currently collaborating on the development of an HTS resource with biochemical and cell-based assays to assess the toxicity of chemical compounds (*2*). As the goal of this project is to use HTS quantitatively to generate data on toxicity, the composition of the compound library naturally varies from that used in drug discovery programs (*2*).

Notwithstanding the enthusiasm for this powerful technology, significant challenges remain with using HTS for hit identification. Particularly vexing is that a large number of hits identified in HTS assays are found to be assay-format-dependent false leads when examined further. Studies have demonstrated that small molecules form colloidal aggregates in aqueous solution that nonspecifically inhibit enzyme activity, which may explain why testing for inhibition is particularly troublesome (*3*). As an example, in a recent HTS analysis, 95% of the hits resulted from compound aggregation concomitant with enzyme inhibition (*4*). Aggregation, however, is not the only cause of artifacts. On page 463 in this issue of *ACS Chemical Biology*, Auld *et al.* (*5*) provide evidence that false leads may be derived from HTS platforms using luciferase reporter-gene assays where the activity arises not from the target but from the stabilization of the luciferase enzyme. As one can envisage similar arti-

10.1021/cb8001864 CCC: \$40.75 Published online August 15, 2008 © 2008 by American Chemical Society

# Editor's ETTER

facts due to stabilization in other reporter-gene assays, caution should be taken while interpreting results solely on the basis of screens. Ultimately, all promising compounds identified by HTS must be subjected to further experimentation to identify genuine hits. Studies such as these are a timely warning that as HTS gains popularity, focus must remain on the assiduous examination of the assay system, the chemical properties of the hits, and the biological relevance of the interaction with the target.

Mahapatia

Anirban Mahapatra Assistant Managing Editor, ACS Chemical Biology

#### REFERENCES

1. Molecular Libraries and Imaging-Overview, NIH Roadmap for Medical Research [cited Aug 1, 2008]. Available from http://nihroadmap.nih.gov/molecularlibraries.

Collins, F. S., Gray, G. M., and Bucher, J. R. (2008) Transforming environmental health protection, *Science 319*, 906 – 907.

- McGovern, S. L., Caselli, E., Grigorieff, N., and Shoichet, B. K. (2002) A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening, J. Med. Chem. 45, 1712–1722.
- Feng, B., Simeonov, A., Jadhav, A., Babaoglu, K., Inglese, J., Shoichet, B., and Austin, C. (2007) A high-throughput screen for aggregation-based inhibition in a large compound library, J. Med. Chem. 50, 2385–2390.
- Auld, D. S., Thome, N., Nguyen, D., and Inglese, J. (2008) A specific mechanism for nonspecific activation in reportergene assays, ACS Chem. Biol. 3, 463–470.